Nodify XL2™ testing supports clinical decision-making so physicians can more confidently identify patients with lung nodules who have a reduced risk of malignancy and may avoid unnecessary invasive procedures.
Nodify XL2 is intended for patients with incidental lung nodules:
We understand the financial stresses that health issues can place on patients. We have created a financial assistance program for patient with financial responsibility to assist in providing affordable care.
To learn more about our financial assistance program, please contact our Customer Care team at 1.866.432.5930.
1. Swensen SJ, Silverstein MD, Ilstrup DM, et. al. "The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules." Arch Intern Med. 1997 Apr 28; 157(8):849-55.
2. Silvestri G et al. "Assessment of plasma proteomics biomarkers ability to distinguish benign from malignant lung nodules." CHEST. 2018 Sept. 154(3):491-500.